Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate

Vaccine

Volumn 13, Issue 12, 1995, Pages 1080-1085

  Gönczöl, Eva ^a   Berencsi, Klara ^a   Pincus, Steve ^b   Endresz, Valeria ^a   Méric, Claude ^c   Paoletti, Enzo ^b   Plotkin, Stanley A ^c  

^a WISTAR INSTITUTE   (United States)

^b Virogenetics Corporation   (United States)

^c Pasteur Mérieux Sérums et Vaccines ^*  (France)

Author keywords

Canarypox gB recombinant; HCMV gB specific CTL; neutralizing antibody

Indexed keywords

CYTOMEGALOVIRUS VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GUINEA PIG; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

ANIMAL; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GUINEA PIGS; HUMAN; MICE; MICE, INBRED CBA; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0029142653     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00048-6     Document Type: Article

References (32)

1. The cytomegalovirus: ubiquitous agents with protean clinical manifestations
2. Human cytomegalovirus infections in immuno-suppressed patients
3. Human cytomegalovirus and atherogenesis
4. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
5. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
6. HLA-restricted T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients
7. Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease
8. Cell surface expression of human cytomegalovirus (HCMV) gp55–116 (gB): use of HCMV recombinant vaccinia virus-infected cells in analsysis of the human neutralizing antibody response
9. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity
10. The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulate both B-and T-cell immune response in humans
11. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity
12. Humoral immunity to glycoprotein B in primary and recurrent cytomegalovirus infections
13. Immune responses to isolated human cytomegalovirus envelope proteins
14. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers
15. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies
16. Induction of complement dependent and independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp 55-116 (gB)
17. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus
18. Recombinant human cytomegalovirus (HCMV)-gB glycoprotein induces gB-specific cell-mediated immunity in mice
19. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB
20. Human cytomegalovirus specific cytotoxic T cells—relative frequency of stage-specific CTL recognizing the 72 kDa immediate-early protein and glycoprotein B expressed by recombinant vaccinia viruses
21. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
22. Potential use of non-replicating vectors as recombinant vaccines
23. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL
24. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
25. Immunization with canarypox virus expressing rabies glycoprotein
26. Highly attenuated poxvirus vectors
27. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system
28. Immune response to human cytomegalovirus infection
29. NYVAC: a highly attenuated strain of vaccinia virus
30. A rapid microneutralization assay for cytomegalovirus
31. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein
32. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination